Immuno-Biological Laboratories Co., Ltd. (TYO:4570)
Japan · Delayed Price · Currency is JPY 941.00
-19.00 (-1.98%)
Aug 6, 2026, 2:12 PM JST
TYO:4570 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,004 | 969 | 816 | 794 | 647 | |
Revenue Growth | 3.61% | 18.75% | 2.77% | 22.72% | 7.47% |
Cost of Revenue | 298 | 335 | 300 | 268 | 271 |
Gross Profit | 706 | 634 | 516 | 526 | 376 |
Selling, General & Admin | 299 | 300 | 282 | 289 | 310 |
Research & Development | 120 | 119 | 129 | 179 | 188 |
Operating Expenses | 425 | 425 | 406 | 474 | 498 |
Operating Income | 281 | 209 | 110 | 52 | -122 |
Interest Expense | -1 | -1 | -1 | -1 | - |
Interest & Investment Income | 1 | - | - | 1 | - |
Earnings From Equity Investments | - | - | - | -203 | -152 |
Currency Exchange Gain (Loss) | 6 | -3 | 8 | 4 | 3 |
Other Non Operating Income (Expenses) | 14 | 5 | 7 | 12 | 28 |
EBT Excluding Unusual Items | 301 | 210 | 124 | -135 | -243 |
Gain (Loss) on Sale of Investments | - | - | - | -130 | - |
Asset Writedown | - | - | - | -14 | -7 |
Other Unusual Items | - | - | - | -1 | - |
Pretax Income | 301 | 210 | 124 | -280 | -250 |
Income Tax Expense | -28 | -39 | -62 | 9 | 8 |
Net Income | 329 | 249 | 186 | -289 | -258 |
Net Income to Common | 329 | 249 | 186 | -289 | -258 |
Net Income Growth | 32.13% | 33.87% | - | - | - |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 |
Shares Change | - | - | - | - | - |
EPS (Basic) | 35.33 | 26.74 | 19.97 | -31.03 | -27.70 |
EPS (Diluted) | 35.33 | 26.74 | 19.97 | -31.03 | -27.70 |
EPS Growth | 32.13% | 33.87% | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 268 | 124 | 117 | 26 | -93 |
Free Cash Flow Per Share | 28.78 | 13.31 | 12.56 | 2.79 | -9.99 |
Dividend Per Share | 6.000 | - | - | - | - |
Dividend Growth | - | - | - | - | - |
Gross Margin | 70.32% | 65.43% | 63.23% | 66.25% | 58.11% |
Operating Margin | 27.99% | 21.57% | 13.48% | 6.55% | -18.86% |
Profit Margin | 32.77% | 25.70% | 22.79% | -36.40% | -39.88% |
Free Cash Flow Margin | 26.69% | 12.80% | 14.34% | 3.28% | -14.37% |
EBITDA | 299 | 224 | 112 | - | - |
EBITDA Margin | 29.78% | 23.12% | 13.73% | - | - |
D&A For EBITDA | 18 | 15 | 2 | - | - |
EBIT | 281 | 209 | 110 | 52 | -122 |
EBIT Margin | 27.99% | 21.57% | 13.48% | 6.55% | -18.86% |